Table 5.
KEGG pathway enrichment analysis of miR-101-3p target genes by DAVID.
| KEGG ID | KEGG term | Count (%) | P value | Gene symbol |
|---|---|---|---|---|
| hsa05200 | Pathways in cancer | 25 (0.4) | 1.41×10−5 | PTGS2, MITF, FOS, CASP3, RAC1, TGFA, RUNX1, CEBPA, RXRB, PIK3CB, VHL, TGFBR1, MET, ITGA2, SMAD2, CDK6, CTNNA1, STK4, FZD4, FZD6, NRAS, MAPK1, CDKN1A, VEGFA, MTOR |
| hsa05211 | Renal cell carcinoma | 10 (0.1) | 1.44×10−4 | MAPK1, NRAS, VHL, PIK3CB, MET, VEGFA, GAB1, RAC1, TGFA, RAP1B |
| hsa05210 | Colorectal cancer | 10 (0.1) | 5.79×10−4 | MAPK1, FOS, CASP3, PIK3CB, TGFBR1, MET, RAC1, SMAD2, FZD4, FZD6 |
| hsa04520 | Adherens junction | 9 (0.1) | 1.44×10−3 | PTPRJ, MAPK1, PVRL1, NLK, TGFBR1, MET, RAC1, SMAD2, CTNNA1 |
| hsa05223 | Non-small cell lung cancer | 7 (0.1) | 4.05×10−3 | MAPK1, NRAS, PIK3CB, RXRB, TGFA, CDK6, STK4 |
| hsa05212 | Pancreatic cancer | 8 (0.1) | 4.15×10−3 | MAPK1, PIK3CB, TGFBR1, VEGFA, RAC1, TGFA, CDK6, SMAD2 |
| hsa05221 | Acute myeloid leukemia | 7 (0.1) | 5.79×10−3 | CEBPA, MAPK1, NRAS, PIK3CB, PIM1, MTOR, RUNX1 |
| hsa05221 | Glioma | 7 (0.1) | 8.65×10−3 | MAPK1, NRAS, CDKN1A, PIK3CB, TGFA, CDK6, MTOR |
| hsa04310 | Wnt signaling pathway | 11 (0.16) | 1.06×10−2 | PSEN1, CCND3, VANGL1, ROCK2, NLK, RAC1, SMAD2, PLCB1, FBXW11, FZD4, FZD6 |
| hsa05218 | Melanoma | 7 (0.1) | 1.52×10−2 | MAPK1, NRAS, CDKN1A, PIK3CB, MET, MITF, CDK6 |
| hsa04150 | mTOR signaling pathway | 6 (0.1) | 1.56×10−2 | MAPK1, PIK3CB, VEGFA, PRKAA1, MTOR, DDIT4 |
| hsa04120 | Ubiquitin mediated proteolysis | 10 (0.1) | 1.57×10−2 | UBE2D3, FBXW7, UBE2A, VHL, UBE2G1, UBE2F, CUL4B, UBE2D1, FBXW11, UBE2B |
| hsa04062 | Chemokine signaling pathway | 12 (0.2) | 1.71×10−2 | MAPK1, NRAS, GNAI3, ROCK2, GNB1, PIK3CB, ADCY6, RAC1, RAP1B, JAK2, PLCB1, CXCL12 |
| hsa04670 | Leukocyte transendothelial migration | 9 (0.1) | 1.88×10−2 | F11R, GNAI3, ROCK2, PIK3CB, RAC1, RAP1B, CTNNA1, CXCL12, CDH5 |
| hsa04370 | VEGF signaling pathway | 7 (0.1) | 1.94×10−2 | MAPK1, NRAS, PTGS2, PIK3CB, VEGFA, SPHK1, RAC1 |
| hsa05220 | Chronic myeloid leukemia | 7 (0.1) | 1.94×10−2 | MAPK1, NRAS, CDKN1A, PIK3CB, TGFBR1, CDK6, RUNX1 |
| hsa04916 | Melanogenesis | 8 (0.1) | 2.22×10−2 | MAPK1, NRAS, GNAI3, MITF, ADCY6, PLCB1, FZD4, FZD6 |
| hsa04510 | Focal adhesion | 12 (0.2) | 2.76×10−2 | MAPK1, CCND3, ROCK2, PIK3CB, MET, VEGFA, RAC1, ITGA2, PIP5K1C, RAP1B, CAPN2, PARVA |
| hsa04360 | Axon guidance | 9 (0.1) | 3.02×10−2 | MAPK1, NRAS, NRP1, GNAI3, PLXNA1, ROCK2, MET, RAC1, CXCL12 |
| hsa04012 | ErbB signaling pathway | 7 (0.1) | 3.70×10−2 | MAPK1, NRAS, CDKN1A, PIK3CB, GAB1, TGFA, MTOR |
| hsa04115 | p53 signaling pathway | 6 (0.1) | 4.36×10−2 | CDKN1A, CASP3, CCND3, ZMAT3, CDK6, ATM |